logo
logo
MTD stock ticker logo

Mettler-Toledo International Inc.

NYSE•MTD
CEO: Mr. Patrick K. Kaltenbach
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1997-11-14
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company's laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection equipment, x-ray systems, check weighing equipment, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company's retail weighing solutions consist of weighing and software solutions, AI-driven image recognition solution, and automated packaging and labelling solutions for the meat backroom. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.
Contact Information
1900 Polaris Parkway, Columbus, OH, 43240, United States
614-438-4511
www.mt.com
Market Cap
$26.93B
P/E (TTM)
31.1
29.6
Dividend Yield
--
52W High
$1.53K
52W Low
$962.54
52W Range
64%
Rank18Top 5.0%
6.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$1.13B+0.00%
4-Quarter Trend

EPS

$14.02+0.00%
4-Quarter Trend

FCF

$184.08M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Net Sales Growth Net sales reached $4.03B USD in 2025, increasing 4% in USD terms, despite soft end-market demand.
Strong Operating Cash Flow Cash provided by operating activities totaled $955.8M USD in 2025, supporting liquidity needs and capital expenditures.
Laboratory Segment Performance Laboratory products/services generated $2.24B USD, growing 3% in USD, driven by process analytics growth.
Sustained R&D Investment Research and development expenses were $199.4M USD in 2025, maintained at approximately 5.0% of net sales.

Risk Factors

Gross Margin Erosion Risk Gross profit margin fell to 59.4% in 2025, reflecting higher tariff costs and unfavorable business mix impacts.
China Concentration Exposure China represents 16% of sales; geopolitical tensions and local economic challenges create significant operational risks.
Cybersecurity Infrastructure Risk Reliance on technology infrastructure creates vulnerability to sophisticated cyber attacks, potentially causing service interruptions and data loss.
Currency Volatility Exposure Strengthening Swiss franc against USD/Euro reduces earnings; 1% change impacts tax-excluded earnings by $2.8M–$3.1M annually.

Outlook

Automation Digitalization Focus Expect continued benefit from market trends toward automation and digitalization, including customer replacement cycles into 2026.
Service Business Expansion Service business delivered strong results, expanding value-added offerings for uptime and regulatory compliance support globally.
Capital Allocation Strategy Board authorized additional $2.75B for share repurchases; $3.7B remaining availability as of year-end 2025.
Strategic Acquisition Focus Pursue "bolt-on" acquisitions leveraging global network, targeting life sciences and distribution channel expansion opportunities.

Peer Comparison

Revenue (TTM)

HUM stock ticker logoHUM
$129.66B
+10.1%
IQV stock ticker logoIQV
$16.31B
+5.9%
LH stock ticker logoLH
$13.95B
+7.2%

Gross Margin (Latest Quarter)

NTRA stock ticker logoNTRA
67.1%
+3.1pp
ILMN stock ticker logoILMN
67.0%
-1.4pp
DXCM stock ticker logoDXCM
62.9%
+0.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ALC$38.02B38.94.4%16.6%
A$32.54B25.219.7%26.2%
IQV$28.40B20.922.3%54.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
8.5%
Steady Growth
4Q Net Income CAGR
20.4%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:Apr 29, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data